SPH3127
Modify Date: 2024-04-03 10:02:57
SPH3127 structure
|
Common Name | SPH3127 | ||
|---|---|---|---|---|
| CAS Number | 1399849-02-5 | Molecular Weight | 444.53 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H32N6O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SPH3127SPH3127 (DRI 18) is a novel, highly potent, and orally active direct renin inhibitor (recombinant human-renin IC50=0.4 nM, human plasma renin activity IC50=0.45 nM). SPH3127 shows antihypertensive effect and can be used in essential hypertension research[1]. |
| Name | SPH3127 |
|---|
| Description | SPH3127 (DRI 18) is a novel, highly potent, and orally active direct renin inhibitor (recombinant human-renin IC50=0.4 nM, human plasma renin activity IC50=0.45 nM). SPH3127 shows antihypertensive effect and can be used in essential hypertension research[1]. |
|---|---|
| Related Catalog | |
| In Vivo | SPH3127 (oral administration; 0-10 mg/kg; once) shows favorable bioavailability in cynomolgus monkeys[1]. SPH3127 (oral administration; 0-3 mg/kg; once) shows a hypotensive effect on tsukuba hypertensive mice[1]. Animal Model: Cynomolgus monkeys pretreated with a low-sodium diet and furosemide[1] Dosage: 0, 1, 3, and 10 mg/kg Administration: Oral administration; 1, 3, and 10 mg/kg; once Result: Inhibited plasma renin activity with the IC50 value of 0.46 nM, and showed hypotensive effect. Animal Model: Tsukuba hypertensive mice (THM)[1] Dosage: 0, 0.3, 1, or 3 mg/kg Administration: Oral administration; 0, 0.3, 1, or 3 mg/kg; once Result: Exhibited a hypotensive effect on tsukuba hypertensive mice in a dose-dependent manner from 0.3 to 3 mg/kg, and showed a maximum hypotensive effect of approximately 30 mmHg at 2-3 h after administration at any dose. |
| References |
| Molecular Formula | C22H32N6O4 |
|---|---|
| Molecular Weight | 444.53 |